LOS ANGELES, Aug. 18, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Sarepta Therapeutics, Inc. ("Sarepta" or "the Company") (NASDAQ: SRPT) for violations of §§10(b) and 20(a) of the Securities...
Related Questions
How might this securities fraud lawsuit affect SRPT’s short‑term stock volatility and price direction?
What is the expected timeline for resolution or settlement, and could it impact upcoming earnings releases or guidance?
Are there broader implications for Sarepta’s pipeline financing or partnership agreements due to the litigation risk?